EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSFHEG00000006140
Gene Symbol: UGCG
3 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSFHEG00000020363
Gene Symbol: WEE1
3 Cross references
206 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSFHEG00000012200
Gene Symbol: YES1
4 Cross references
197 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSFHEG00000008565
Gene Symbol: ACHE
3 Cross references
232 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSFHEG00000003733
Gene Symbol: ACVR2B
3 Cross references
196 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSFHEG00000007446
Gene Symbol: LOC105920743
3 Cross references
194 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSFHEG00000020831
Gene Symbol: ADORA1
1 Cross references
207 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSFHEG00000010747
Gene Symbol: ADORA2A
3 Cross references
200 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSFHEG00000005712
Gene Symbol: ADORA2A
3 Cross references
188 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSFHEG00000006486
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSFHEG00000017578
Gene Symbol: ADORA3
3 Cross references
226 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSFHEG00000015610
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).